title: Effect of Fraxiparine and heparin on experimental tumor metastasis in mice.
abstract: BACKGROUND
  Low molecular weight heparins (LMWH) have become increasingly important in anticoagulant therapy. Antitumor and antimetastatic activity of heparin and LMWH-s have also been reported.
  
  
  METHODS
  Fraxiparine, a new modified LMW-H, was tested for antimetastatic effect using 3LL-HH intravenous, B16 intra-foot pad and 3LL-HH intrasplenic models in C57 Bl/6 mice. The dose of Fraxiparine was 38, 57 and 172 IU/kg, respectively. Heparin (100 IU/kg) was used as a positive control. Both pre-treatment (starting 6 hours before tumor inoculation) and post-treatment (starting 24 hours after tumor inoculation), followed by daily injections, were applied in the intra-foot pad and intrasplenic models. In the intravenous model, only a single dose was administered one hour after tumor cell injection.
  
  
  RESULTS
  Fraxiparine at the dose of 57 IU/kg was significantly antimetastatic in the intravenous model. Continuous treatment, starting 6 hours before tumor inoculation, with 173 IU/kg Fraxiparine resulted in a strong inhibition of lung metastases in the intra-foot pad model, but was ineffective in the intrasplenic model. Heparin did not influence the metastasis number in any of the metastasis models.
  
  
  CONCLUSIONS
  These data may be of importance in the anticoagulant treatment of human cancer patients.
authors.affiliation: First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. bszende@korb1.sote.hu
authors.forename: Béla
authors.initials: B
authors.lastname: Szende
authors.forename: Sándor
authors.initials: S
authors.lastname: Paku
authors.forename: Gergely
authors.initials: G
authors.lastname: Rácz
authors.forename: László
authors.initials: L
authors.lastname: Kopper
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000556:secondary*; D051379:Mice; D008810:Mice, Inbred C57BL; D017762:Nadroparin / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D017762:Nadroparin